olaparib Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Jul 7, 2022 Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium Apr 28, 2022 Merck Q1 Revenues Increase 50 Percent Driven by Keytruda Apr 11, 2022 UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study Mar 17, 2022 Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing Premium Mar 11, 2022 FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer Feb 18, 2022 PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions Premium Feb 10, 2022 AstraZeneca Q4 Oncology Revenues Grow 20 percent Feb 3, 2022 Merck Q4 Revenues Grow 24 Percent With Keytruda Driving Sales Nov 30, 2021 AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer Nov 12, 2021 AstraZeneca's Q3 Oncology Revenues Grow 18 Percent Oct 28, 2021 Merck Q3 Revenues Grow 20 Percent With Keytruda as Top Seller Sep 7, 2021 Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
